Cheaper cancer drug on the horizon? new biosimilar QL2109 tested in healthy men
NCT ID NCT07400744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tests QL2109, a biosimilar to the multiple myeloma drug Darzalex, in 102 healthy Chinese men. The goal is to see if the body processes QL2109 similarly to Darzalex and to check for side effects. It does not test the drug's ability to treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL2109 (a biosimilar to daratumumab)
- What this could lead to
- If QL2109 works like Darzalex, it could offer a more affordable treatment option for multiple myeloma.
- What could go wrong
- This is an early Phase 1 study in healthy people, not patients. It only checks drug levels and safety, not whether it fights cancer. Success is far from certain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact